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omparison of Drug-Eluting Stents Versus
are-Metal Stents for Treating ST-Segment
levation Myocardial Infarction
ehdi H. Shishehbor, DO, MPH, Reza Amini, MD, Leonardo P. J. Oliveria, MD,
nder M. Singh, MD, MS, Peter Kelly, MD, Deepak L. Bhatt, MD, Samir R. Kapadia, MD,
tephen G. Ellis, MD, Patrick L. Whitlow, MD, Sorin J. Brener, MD
leveland, Ohio
bjectives We sought to examine the clinical outcomes of patients treated with drug-eluting stents
DES) compared with bare-metal stents (BMS) during primary angioplasty for ST-segment elevation
yocardial infarction (STEMI).
ackground Pathophysiologic studies suggest that the use of DES for STEMI may be associated
ith stent thrombosis and increased clinical events. However, although short-term data exist, long-
erm follow-up is lacking.
ethods Patients who presented with STEMI from January 2002 to May 2007 to our institution
ere included. In addition to multivariable adjusted analysis, propensity analysis for stent choice
as performed. The primary end point was the composite of death or target lesion revascularization
TLR).
esults Of the 804 patients, 699 underwent stenting and met our study criteria. There were 152
omposite events over a median follow-up of 1.7 years. In a multivariable Cox model, DES use was
ssociated with a trend toward lower death or TLR compared with BMS (adjusted hazard ratio [HR]
.72, 95% conﬁdence interval [CI], 0.50 to 1.02, p  0.06). However, this was mainly due to lower
LR (adjusted HR 0.60, 95% CI, 0.36 to 0.98, p  0.043). Similarly, DES was associated with a trend
oward lower death or TLR compared with BMS in the propensity-matched patients (adjusted HR
.65, 95% CI 0.42 to 1.00, p  0.05). This was mainly due to lower TLR in the DES patients (adjusted
R 0.52, 95% CI 0.28 to 0.96, p  0.04).
onclusions Both DES and BMS are effective in the setting of STEMI; however, DES is associated
ith lower TLR without an increase in all-cause mortality. (J Am Coll Cardiol Intv 2008;1:227–32)
2008 by the American College of Cardiology Foundation
rom Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio. Dr. Shishehbor is supported in part by the
ase Western Reserve University/Cleveland Clinic National Institutes of Health CTSA (1KL2RR024990).anuscript received December 28, 2007; revised manuscript received February 28, 2008, accepted March 15, 2008.
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228urrently 42% of patients who present with ST-segment
levation myocardial infarction (STEMI) are treated with
rimary percutaneous coronary intervention (PCI) and an
dditional 19% undergo rescue PCI (1). Drug-eluting stents
DES) became available in the U.S. in March 2003 and
ere initially used in 70% to 80% of patients undergoing
CI including those who presented with STEMI (2).
owever, the initial enthusiasm was tempered by data on
ate-stent thrombosis, which were first reported in October
004 (3–5). Furthermore, plaque rupture leading to STEMI
s accompanied by a large thrombus burden and may
ncrease the risk for stent thromosis (6).
See page 233
To date, there are 5 published randomized controlled
rials (RCTs) that have evaluated the use of DES versus
are-metal stents (BMS) is the setting of STEMI (7–11).
However, these studies were un-
derpowered to detect small dif-
ferences in major adverse cardiac
events and lacked long-term
follow-up (12). Therefore, we
sought to examine the long-term
outcomes of DES versus BMS
for treating patients with STEMI
in a large cohort of patients at a
single referral center.
Methods
Study population. From January
1, 2002, onward, all patients
presenting with STEMI to the
Cleveland Clinic cardiac catheter-
zation laboratory were included in a prospectively collected
ngoing registry. Concomitantly, all patients undergoing PCI
ere included in an ongoing registry for which baseline
haracteristics, angiographic data, and medications are col-
ected at the time of coronary intervention. These 2 data-
ases were merged for this analysis. The decision to choose
particular stent was completely based on the operators’
reference. Patients who presented with STEMI but did
ot undergo stenting (because of medical management
lone or balloon angioplasty alone) were excluded. The
nstitutional Review Board of the Cleveland Clinic waived
equirements for informed consent for the institutional PCI
nd STEMI registries.
ngiographic characteristics. Data on procedural character-
stics and device use were captured prospectively. Location
f the culprit lesion was defined as proximal left anterior
escending, middle or distal left anterior descending, right
bbreviations
nd Acronyms
MS  bare-metal stent(s)
I  confidence interval
ES  drug-eluting stent(s)
R  hazard ratio
CI  percutaneous
oronary intervention
CT  randomized clinical
rial
TEMI  ST-segment
levation myocardial
nfarction
LR  target lesion
evascularizationoronary artery, or left circumflex coronary artery. Ilinical end points. The primary end point was the com-
osite of death from any cause or target lesion revascular-
zation (TLR) (PCI or coronary artery bypass grafting). All
atients were prospectively followed for adverse cardiovas-
ular events through hospital record review and the Social
ecurity Death Index.
tatistical analysis. Baseline and angiographic characteris-
ics of DES and BMS patients were compared with the use
f the Wilcoxon rank-sum test for continuous variables and
he chi-square test for categorical variables. Differences in
utcome between the 2 stent types were tested in unadjusted
aplan-Meier curves and multivariable Cox proportional
azards analysis. Adjusted models accounted for baseline
emographic features, angiographic variables, treatment
ssignment, door-to-balloon time, peak creatinine kinase
evels, and ultrasensitive C-reactive protein (Table 1). Step-
ise selection was used to select statistically significant
onfounders. However, results were not substantially differ-
nt when this method was compared with a nonparsimoni-
us model. Therefore, the results shown represent nonpar-
imonious models. The proportional hazards assumption
as confirmed by testing the weighted Schoenfeld residuals
nd by plotting hazard ratio against time plots for selected
ariables.
To address potential biases, propensity analysis was per-
ormed. Nonparsimonious logistic regression models were
sed to generate a propensity score for stent choice. We
onsidered all variables listed in Table 1 for this model,
xcluding procedural success. Each subject from the DES
roup was matched with a patient who received BMS using
he derived propensity score. Subsequently, we performed
n adjusted multivariable analysis that incorporated all
aseline characteristics in addition to the propensity score
or the propensity-matched patients. Matching is performed
o the nearest fifth digit.
esults
aseline characteristics. A total of 804 patients presented
o the cardiac catheterization laboratory after a presump-
ive diagnosis of STEMI. Of these, 24 had normal
oronaries, 46 received balloon angioplasty only, and 35
atients were lost to follow-up. Therefore, 699 patients
et our study criteria. Baseline and target lesion charac-
eristics according to stent type are presented in Table 1.
n general, patient and procedural characteristics were
imilar between both groups. However, patients under-
oing DES were more likely to be in Killip class IV.
dditionally, patients undergoing DES implantation
ere more likely to be treated with beta-blockers and
tatins. The DES were less often used in saphenous vein
rafts. The predominant procedural anticoagulation was
ased on unfractionated heparin and glycoprotein IIb/
IIa inhibitors (Table 1).
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229linical outcomes. A cumulative of 152 events occurred
uring a mean follow-up of 1.7 years. In the unadjusted
Table 1. Baseline and Procedural Characteristics Based on Stent Type*
Characteristics
DES
(n  344)
BMS
(n  355) p Value
Age, yrs 60 13 61 14 0.48
Male, % 211 (61) 251 (71) 0.009
Body mass index 30 6 30 7 0.99
Left ventricular ejection fraction 44 10 43 10 0.16
Door to balloon time, min
(median, interquartile range)
109 (45–264) 109 (39–278) 0.85
Malignancy 8 (2) 24 (7) 0.005
Risk factors, %
Cigarette smoking 144 (42) 141 (40) 0.56
Insulin-dependent diabetes mellitus 21 (6) 33 (9) 0.11
Noninsulin-dependent diabetes
mellitus
53 (15) 52 (15) 0.78
Medical history, %
Prior myocardial infarction 107 (31) 108 (30) 0.84
Peripheral arterial disease 15 (4) 21 (6) 0.35
Prior coronary artery bypass
surgery
25 (7) 24 (7) 0.79
Stroke or transient ischemic attack 18 (5) 25 (7) 0.32
Killip class IV, % 180 (52) 136 (38) 0.001
Medications, %
Aspirin 313 (91) 318 (90) 0.53
Clopidogrel 344 (100) 355 (100) 1.00
Heparin 268 (78) 260 (73) 0.15
Glycoprotein IIb/IIIa inhibitors 311 (90) 313 (88) 0.34
Beta-blockers 305 (89) 294 (83) 0.03
Angiotensin converting enzyme
inhibitors
236 (69) 221 (62) 0.08
Statins 325 (94) 299 (84) 0.001
Cardiac and inﬂammatory markers
Pre-procedural usCRP, mg/l 13 26 17 36 0.11
Creatine kinase, U/l 1,809 2,304 2,165 4,422 0.16
Creatine kinase-MB fraction, ng/ml 199 331 188 255 0.94
Location of culprit lesion, %
Proximal left anterior descending
artery
60 (17) 51 (14) 0.36
Mid or distal left anterior
descending artery
101 (29) 87 (25) 0.15
Left circumﬂex artery 46 (13) 41 (12) 0.47
Right coronary artery 137 (40) 176 (50) 0.009
Angiographic characteristics
Reference vessel diameter, mm 3.16 0.41 3.31 0.62 0.001
Lesion length, mm 19.1 11.3 19.4 13.7 0.35
Stent Length, mm 23.6 7.0 26.5 19.6 0.50
Saphenous vein graft, % 7 (2) 17 (5) 0.05
Number of diseased vessels
1 283 (82) 265 (75) 0.01
2 49 (14) 65 (18) 0.15
3 12 (3) 23 (6) 0.07
Continuednalysis DES use was significantly associated with loweromposite end point of death or TLR (Fig. 1, Table 2). In
ultivariable adjusted Cox proportional hazard model,
here was a trend for lower events in the DES group, which
as mainly due to a reduction in TLR (Table 2). Impor-
antly, the rate of death was similar in both groups.
ropensity-matched analysis. To account for the differences
hat existed in the nonpropensity-matched patients, pro-
ensity analysis was performed. After generating a propen-
ity score (c-statistic  0.72), 240 of the 344 patients who
Table 1. Continued
Characteristics
DES
(n  344)
BMS
(n  355) p Value
American College of Cardiology
lesion score, %
A 5 (1) 10 (3) 0.21
B1 31 (9) 29 (8) 0.69
B2 111 (32) 91 (26) 0.05
C 196 (57) 225 (63) 0.08
Preprocedural TIMI ﬂow
grade 3, %
107 (31) 111 (31) 0.96
Postprocedural TIMI ﬂow
grade 3, %
335 (97) 338 (95) 0.13
Number of stents, %
1 229 (67) 224 (63) 0.34
2 79 (23) 87 (25) 0.63
3 36 (10) 44 (12) 0.42
Procedural success, % 334 (97) 331 (93) 0.02
Procedure year 0.004
2002 2 (0.6) 66 (19)
2003 15 (4) 72 (20)
2004 91 (26) 28 (8)
2005 105 (30) 32 (9)
2006 116 (34) 72 (20)
2007 15 (4) 85 (24)
BMS  bare-metal stent(s); DES  drug-eluting stent(s); TIMI  Thrombolysis In Myocardial
Infarction; usCRP ultrasensitive C-reactive protein.
Figure 1. Kaplan-Meier Curves for Overall Nonpropensity-Matched
Patients According to Stent Type (n  699)
Note freedom from all-cause mortality and target lesion revascularization
among those receiving drug-eluting compared with bare-metal stents.
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230eceived DES were matched with a patient who received
MS. No significant differences were noted in more than 30
aseline characteristics for the propensity-matched subjects
Table 3).
A total of 95 events occurred during a mean follow-up of
.8 years. Both in the unadjusted and multivariable adjusted
odels, there was a trend toward lower rates of death or
LR with DES, which again was mainly driven by a
eduction in TLR (Fig. 2, Table 2).
iscussion
n this cohort of consecutive, unselected patients who
resented with STEMI, PCI with DES was associated with
lower TLR rate and a trend toward lower rate of the
omposite end point of death or TLR. These results
ersisted despite multiple statistical adjustments, including
ropensity analysis. Importantly, there was no difference in
Table 2. Unadjusted and Multivariable Adjusted Hazard Ratios for the
Primary and Secondary End Points
No. of Events
DES
Group
(%)
BMS
Group
(%)
Hazard Ratio
(95% Confidence
Interval)
p
Value
Total population (n  699) n  344 n  355
Composite of death or target
lesion revascularization
(n  152)
61 (18) 91 (26) — —
Unadjusted — — 0.60 (0.43–0.83) 0.002
Adjusted — — 0.72 (0.50–1.02) 0.06
All-cause mortality (n  76) 30 (9) 46 (13) — —
Unadjusted — — 0.66 (0.41–1.04) 0.08
Adjusted — — 1.18 (0.69–2.02) 0.55
Target lesion
revascularization
(n  81)
34 (10) 47 (13) — —
Unadjusted — — 0.65 (0.41–1.01) 0.06
Adjusted — — 0.60 (0.36–0.98) 0.043
Propensity-matched
population (n  480)
n  240 n  240
Composite of death or target
lesion revascularization
(n  95)
41 (17) 54 (22) — —
Unadjusted — — 0.64 (0.43–0.97) 0.03
Adjusted — — 0.65 (0.42–1.00) 0.05
All-cause mortality (n  43) 22 (9) 21 (9) — —
Unadjusted — — 0.98 (0.54–1.79) 0.95
Adjusted — — 1.17 (0.57–2.42) 0.67
Target lesion
revascularization
(n  54)
21 (9) 33 (14) — —
Unadjusted — — 0.58 (0.33–1.01) 0.05
Adjusted — — 0.52 (0.28–0.96) 0.04
Abbreviations as in Table 1.he incidence of all-cause mortality between the 2 groups. aA number of concerns have led to lower use of DES in
atients with STEMI (4,12,13), including the risk of late
tent thrombosis, impaired endothelial function distal to
tent, and excessive platelet activation (14). Mechanistically,
hese abnormalities may be related to delayed arterial
ealing of the necrotic core characterized by lack of com-
lete re-endothelialization and persistence of fibrin within
he ruptured plaque when compared with BMS (14).
owever, despite these concerns all RCTs to date show
ower rate of restenosis with no significant difference for
eath or myocardial infarction (7–10).
Recently, Kastrati et al. (15) published a meta-analysis of
published and 3 unpublished randomized clinical trials in
he setting of STEMI (15). The follow-up duration was 12
o 24 months among 2,786 patients. These authors showed
imilar composite end points between DES and BMS for
TEMI, with lower TLR in patients that received DES.
owever, concerns have been raised about the lack of power
nd long-term follow-up in each of these individual trials
14). Additionally, these meta-analyses are from random-
zed clinical trials and not the “real-world” setting. There-
ore, we attempted to address this question in 699 patients
ho underwent PCI in the setting of STEMI. There were
total of 152 composite events with 77 deaths, which gave
s adequate power to assess differences between the 2 stent
ypes. Additionally, propensity analysis and matching were
erformed and demonstrated consistent results in the
atched cohort.
tudy limitations. Our study had several limitations. This
tudy was an observational one on prospectively collected
ata; therefore, it is prone to a number of biases that are
resent in such study design. To address some of these
imitations, we conducted propensity analysis. However,
ropensity analysis can only account for variables that are
easured. Therefore, there may remain biases that are not
ccounted for in this analysis such as presence of cancer. It
s not clear why some patients received DES whereas other
eceived BMS. By using propensity analysis, we adjusted for
actors that are known to impact the decision by a surgeon
egarding the use of DES versus BMS in a patient, such as
ultivessel coronary artery disease, lesion length, vessel
iameter, and the presence of diabetes mellitus and severe
o-morbidity, such as malignancy. Even after these adjust-
ents, patients who received a DES had significantly lower
ates of reintervention.
The present study is from a tertiary care center and may
ot be generalizable. However, our results are consistent
ith previous randomized clinical trials and observational
tudies that have examined safety and efficacy of DES versus
MS. Another limitation is lack of knowledge on duration
f dual antiplatelet therapy used in the 2 groups of patients
nd the intensity and extent of concomitant medical ther-
py. Finally, we began capturing the occurrence of stent
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231hrombosis in our registry in mid 2006, and thus we did not
ave accurate data on stent thrombosis or myocardial
nfarction.
onclusions
ur results extend the conclusions of previous randomized
linical trials and observational studies and confirm the
uperiority of DES in decreasing the need for clinically
elevant TLR without increasing the risk of death. The use
f DES in STEMI in this analysis was not associated with
ncreased mortality; however, the impact of DES on sub-
cute thrombosis and myocardial infarction in this study
annot be assessed. Data from ongoing RCTs should
rovide further guidance about the optimal approach to
tenting in AMI.
Figure 2. Kaplan-Meier Curves for Overall Propensity-Matched Patients
According to Stent Type (n  480)
Note freedom from all-cause mortality and target lesion revascularization
Table 3. Continued
Characteristics
DES
(n  240)
BMS
(n  240) p Value
American College of Cardiology
lesion score
A 5 (2) 7 (3) 0.56
B1 19 (8) 22 (9) 0.62
B2 63 (26) 69 (29) 0.54
C 153 (64) 142 (59) 0.30
Preprocedural TIMI ﬂow grade 3 64 (27) 86 (36) 0.03
Postprocedural TIMI ﬂow grade 3 231 (96) 234 (98) 0.43
No. of stents
1 164 (68) 152 (63) 0.25
2 53 (22) 56 (23) 0.74
3 23 (10) 23 (10) 0.20
Procedural success, % 236 (98) 224 (93) 0.006
Abbreviations as in Table 1.Table 3. Baseline and Procedural Characteristics for Propensity-Matched
Patients According to Stent Type
Characteristics
DES
(n  240)
BMS
(n  240) p Value
Age, yrs 60 13 60 14 0.88
Male, % 160 (67) 156 (65) 0.70
Body mass index 30 6 30 6 0.94
Left ventricular ejection fraction 43 10 43 9 0.59
Door to balloon time, min
(median, interquartile range)
216 173 208 173 0.50
Malignancy 8 (3) 8 (3) 1.00
Risk factors, %
Cigarette smoking 102 (42) 103 (43) 0.93
Insulin-dependent diabetes mellitus 16 (7) 16 (7) 1.00
Noninsulin-dependent diabetes
mellitus
41 (17) 38 (16) 0.71
Medical history, %
Prior myocardial infarction 75 (31) 79 (33) 0.70
Peripheral arterial disease 13 (5) 13 (5) 1.00
Prior coronary artery bypass
surgery
18 (8) 12 (5) 0.26
Stroke or transient ischemic attack 15(6) 15 (6) 1.00
Killip class IV, % 109 (45) 106 (44) 0.78
Medications, %
Aspirin 217 (90) 219 (91) 0.75
Clopidogrel 240 (100) 240 (100) 1.00
Heparin 188 (78) 177 (74) 0.24
Glycoprotein IIb/IIIa inhibitors 219 (91) 215 (90) 0.54
Beta-blockers 209 (87) 207 (86) 0.79
Angiotensin converting enzyme
inhibitors
160 (67) 160 (67) 1.00
Statins 223 (93) 215 (90) 0.19
Cardiac and inﬂammatory markers
Preprocedural usCRP 13 28 14 30 0.15
Creatine kinase, U/l 1,818 2,367 1,955 1,909 0.73
Creatine kinase-MB fraction, ng/ml 199 309 205 289 0.35
Location of culprit lesion, %
Proximal left anterior descending
artery
39 (16) 36 (15) 0.71
Mid or distal left anterior
descending artery
62 (26) 62 (26) 1.00
Left circumﬂex artery 33 (14) 34 (14) 0.90
Right coronary artery 106 (44) 107 (45) 0.93
Angiographic characteristics
Reference vessel diameter, mm 3.2 0.41 3.2 0.55 0.31
Lesion length, mm 19.2 11.4 19.1 13.5 0.14
Stent length, mm 24.8 7.5 23.9 14.1 0.24
Saphenous vein graft, % 6 (2) 5 (2) 0.76
Number of diseased vessels
1 190 (79) 189 (79) 0.91
2 41 (17) 39 (16) 0.81
3 9 (4) 12 (5) 0.65among those receiving drug-eluting compared with bare-metal stents.
R
A
t
H
s
R
1
1
1
1
1
1
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 1 , N O . 3 , 2 0 0 8
J U N E 2 0 0 8 : 2 2 7 – 3 2
Shishehbor et al.
DES Versus BMS for STEMI
232eprint requests and correspondence: Dr. Sorin J. Brener,
ssociate Professor of Medicine, Director, Cardiac Catheteriza-
ion Laboratory and Interventional Cardiology, NY Methodist
ospital, 506 Sixth Street, Brooklyn, New York 11215. E-mail:
jb9005@nyp.org.
EFERENCES
1. Eagle KA, Goodman SG, Avezum A, Budaj A, Sullivan CM,
Lopez-Sendon J. Practice variation and missed opportunities for
reperfusion in ST-segment-elevation myocardial infarction: findings
from the Global Registry of Acute Coronary Events (GRACE). Lancet
2002;359:373–7.
2. Maisel WH. Unanswered questions—drug-eluting stents and the risk
of late thrombosis. N Engl J Med 2007;356:981–4.
3. McFadden EP, Stabile E, Regar E, et al. Late thrombosis in drug-
eluting coronary stents after discontinuation of antiplatelet therapy.
Lancet 2004;364:1519–21.
4. Holmes DR Jr., Kereiakes DJ, Laskey WK, et al. Thrombosis and
drug-eluting stents: an objective appraisal. J Am Coll Cardiol 2007;50:
109–18.
5. Bavry AA, Kumbhani DJ, Helton TJ, Borek PP, Mood GR, Bhatt DL.
Late thrombosis of drug-eluting stents: a meta-analysis of randomized
clinical trials. Am J Med 2006;119:1056–61.
6. Joner M, Finn AV, Farb A, et al. Pathology of drug-eluting stents in
humans: delayed healing and late thrombotic risk. J Am Coll Cardiol
2006;48:193–202.7. Laarman GJ, Suttorp MJ, Dirksen MT, et al. Paclitaxel-eluting versus
uncoated stents in primary percutaneous coronary intervention. N Engl
J Med 2006;355:1105–13.
8. Menichelli M, Parma A, Pucci E, et al. Randomized trial of Sirolimus-
Eluting Stent Versus Bare-Metal Stent in Acute Myocardial Infarction
(SESAMI). J Am Coll Cardiol 2007;49:1924–30.
9. Spaulding C, Henry P, Teiger E, et al. Sirolimus-eluting versus
uncoated stents in acute myocardial infarction. N Engl J Med 2006;
355:1093–104.
0. Valgimigli M, Percoco G, Malagutti P, et al. Tirofiban and sirolimus-
eluting stent vs abciximab and bare-metal stent for acute myocardial
infarction: a randomized trial. JAMA 2005;293:2109–17.
1. van der Hoeven BL, Liem SS, Jukema JW, et al. Sirolimus-eluting
stents versus bare-metal stents in patients with ST-segment eleva-
tion myocardial infarction: 9-month angiographic and intravascular
ultrasound results and 12-month clinical outcome results from the
MISSION! Intervention Study. J Am Coll Cardiol 2008;51:
618–26.
2. Bavry AA, Bhatt DL. Acute myocardial infarction and drug-eluting
stents: a green light for their use or time for measured restraint? Am
Heart J 2007;153:719–21.
3. Suryapranata H, De Luca G, van’t Hof AW, et al. Is routine stenting
for acute myocardial infarction superior to balloon angioplasty? A
randomised comparison in a large cohort of unselected patients. Heart
2005;91:641–5.
4. Luscher TF, Steffel J, Eberli FR, et al. Drug-eluting stent and coronary
thrombosis: biological mechanisms and clinical implications. Circula-
tion 2007;115:1051–8.
5. Kastrati A, Dibra A, Spaulding C, et al. Meta-analysis of randomized
trials on drug-eluting stents vs. bare-metal stents in patients with acute
myocardial infarction. Eur Heart J 2007;28:2706–13.
